Medtronic Submits IPO Filing for Diabetes Business MiniMed, Plans Nasdaq Listing Under Ticker 'MMED'

Dec 20, 2025 10:00 CST Updated 10:00

Medtronic

Medical Device Manufacturer

Medtronic announced that its diabetes business (MiniMed) has submitted an S-1 form registration statement to the U.S. Securities and Exchange Commission (SEC) for the proposed initial public offering (IPO) of its newly issued common stock. This business separation is expected to be completed through a series of capital market transactions, with the preferred path being an initial public offering followed by a subsequent spin-off.

MiniMed Plans to Apply for NASDAQ Global Select Market Listing, Ticker Symbol "MMED". The number of shares and price range for this offering have not yet been determined. The initial public offering is expected to commence after the SEC completes its review process, subject to market and other conditions.

Background

202001Medtronic Acquires MiniMed for $3.7 BillionMiniMedIs a leading insulin pump manufacturer. Medtronic acquisitionMiniMed, which has brought Medtronic into the diabetes treatment field and made Medtronic the leader in this area.。

HoweverThe diabetes business is the smallest segment of Medtronic, accounting for approximately 8% of the company's total sales. This segment includesContinuous Glucose Monitor (CGM), Insulin Pump and Associated Consumables.

But in recent years, the competition in the insulin pump field has become increasingly fierce. Medtronic's transition in the insulin pump business has faced obstacles, and it has also been affected by quality issues. This has led to the diabetes business growth not meeting the expectations of aggressive investors and has weighed down the stock price.

Lifting the 2021 FDA Warning Letter on the MiniMed Insulin Pump (Involving Quality System Deficiencies such as Risk Assessment and Adverse Event Reporting);
Medtronic 2023Medtronic announcesAcquires South Korean Company for $738 MillionEOFlow (the world's second developer of tubeless, disposable patch insulin pumps), but ultimately because EOFlow infringedInsulet intellectual property issues were forced to terminate;

Therefore, Medtronic announced in May this year that it would spin off its diabetes business.Medtronic's official explanation is based on two core factors:

Strategic Focus: Enable the parent company and "NewCo" to each focus on their core businesses.
Sales Model: The commercial path of diabetes business directly targeting consumers fundamentally differs from the group's traditional B2B model.